CRISPR-Cas9: A Breakthrough Tool to Repair the DYSF Gene

By SWA

The Power of CRISPR Gene Editing

CRISPR-Cas9 is a revolutionary gene-editing tool that allows scientists to make precise changes to the DNA sequence. It works by using a guide RNA (gRNA) to target the specific mutation in the DYSF gene and a Cas9 enzyme to cut the DNA at the mutation site. This triggers the cell’s natural repair mechanisms to correct the error, restoring normal function to the dysferlin protein.

Research Highlights

At the ECRC, researchers extracted muscle stem cells from patients with Limb-Girdle Muscular Dystrophy Type 2B. Using CRISPR, they corrected the genetic mutation in the DYSF gene, leading to the production of functional dysferlin protein in cell cultures. The team then transplanted the corrected cells back into mouse models, where:

  • The dysferlin protein restored membrane repair capability.
  • Muscle degeneration slowed, and muscle strength improved.

These promising results pave the way for clinical trials in humans, where similar techniques could be used to edit patients' muscle cells, correct the mutation, and transplant the repaired cells back into affected muscles.

Age of Symptom Onset in Dysferlinopathies

The symptoms of dysferlin protein deficiency typically appear during late adolescence or early adulthood. However, the age of onset can vary depending on the type of dysferlinopathy and the severity of the DYSF mutation:

  • LGMD2B: Onset is most common in the late teens to early 20s, with progressive weakness in the hips and shoulders.
  • Miyoshi Myopathy: Symptoms usually begin in the late teens or 20s, starting with calf muscle weakness and atrophy.
  • Distal Myopathy with Anterior Tibial Onset: A milder, late-onset form that begins in the 30s or 40s.

Why Does Onset Happen Later?

The delayed onset of symptoms is due to the body's ability to initially compensate for dysferlin deficiency. Over time, however:

  1. Cumulative muscle damage from daily activity overwhelms the repair system.
  2. Muscle reserves are depleted as damaged cells are replaced with scar tissue (fibrosis).
  3. Inflammation and chronic stress further accelerate muscle degeneration.

Future Implications of the Discovery

The use of CRISPR-Cas9 to correct DYSF gene mutations represents a potential cure for dysferlinopathies by addressing the root cause of the disease. While challenges remain, such as ensuring long-term safety and effectiveness, this discovery could lead to:

  • Personalized gene therapies for patients with specific DYSF mutations.
  • Wider applications of CRISPR for other forms of muscular dystrophy and genetic disorders.
  • A better quality of life for individuals affected by progressive muscle-wasting diseases.

Conclusion

The discovery by the ECRC and Max Delbrück Center researchers marks a turning point in the treatment of dysferlinopathies. By leveraging CRISPR-Cas9 gene-editing technology, scientists have shown that it is possible to repair mutations in the DYSF gene, restore dysferlin protein function, and potentially halt or reverse the effects of muscle wasting. As clinical trials move forward, this breakthrough could offer new hope to thousands of individuals suffering from dysferlin-related muscular dystrophies worldwide.

Reference: 

Mit CRISPR gegen Muskelschwund https://www.charite.de/forschung/themen_forschung/2024/muskelschwund

Developing a CRISPR therapy for muscular dystrophy

Gene-editing in patient and humanized-mice primary muscle stem cells rescues dysferlin expression in dysferlin-deficient muscular dystrophy https://www.nature.com/articles/s41467-024-55086-0

Additional information: Dysferlin Protein: Key Roles, Locations of Production, and Nutritional Strategies for Support

Dysferlin gene regulation epigenetics: https://scholar.google.com/scholar?hl=de&as_sdt=0%2C5&q=dysferlin+gene+regulation+epigenetics&btnG=

 © 2000-2025 Sieglinde W. Alexander. All writings by Sieglinde W. Alexander have a fife year copy right. Library of Congress Card Number: LCN 00-192742 ISBN: 0-9703195-0-9

 

Comments

Post a Comment

Popular posts from this blog

Toxic Skin Condition Post-mRNA COVID-19 Vaccination

By SWA
Image
Identifying Severe Skin Conditions Post-Vaccination Following administration of the BioNTech mRNA vaccine, a small subset of individuals may develop severe and complex reactions. These reactions are often misdiagnosed or misunderstood due to their rarity and diverse presentation. This essay examines a case characterized by severe skin conditions, systemic symptoms, and complications such as hypercalcemia and crystal formation. It highlights the need for accurate diagnosis, holistic management, and increased awareness of these rare but significant vaccine-related adverse events. Initial Symptoms and Misdiagnoses Severe symptoms began shortly after the first dose of the BioNTech vaccine, initially presenting as petechiae, diagnosed by a rheumatologist. However, following the second dose, symptoms rapidly escalated, resulting in intense burning pain and thinning of the skin. The skin on the legs and thighs became paper-thin and could tear with the slightest touch, with the affected area e...
Read more

Dysferlin Protein: Key Roles, Genetic Locations

By SWA
Image
The purpose of this article is to share and discuss the details of a new discovery, which is highlighted within: CRISPR-Cas9: A Breakthrough Tool to Repair the DYSF Gene The dysferlin protein plays an essential role in maintaining the integrity of muscle cell membranes, particularly in tissues that endure significant mechanical stress, such as skeletal and cardiac muscles . Encoded by the DYSF gene , dysferlin is indispensable for repairing damaged cell membranes after injury caused by muscle contraction or external forces. This article explores the main locations where dysferlin is produced, its role in muscle repair, and supportive nutritional and therapeutic strategies for individuals with dysferlin deficiency, such as those affected by dysferlinopathies (e.g., Limb-Girdle Muscular Dystrophy Type 2B or Miyoshi Myopathy). Currently, there is no definitive answer as to why the severity of dysferlin protein expression or depletion varies. Do pathogens play a role in the methylation o...
Read more

Is ME CFS connected to Spinal Muscular Atrophy (SMA) or Post Polio?

By SWA
Image
Today, I understand why Spinal Muscular Atrophy (SMA) received little attention, particularly in the mid-50s. This complex and debilitating genetic illness was poorly understood, and patients' symptoms were often minimized or even dismissed. For more information, please visit the Spinal Muscular Atrophy (SMA) page on MalaCards . Even now, many neurologists lack detailed knowledge of SMA, and comprehensive examinations mentioned in research are rarely pursued. In 2008, while investigating permanent adrenal insufficiency, an MRI ordered by my endocrinologist unexpectedly revealed Chiari Malformation II. However, surgery in 2009 brought no improvement. In 2010, a DNA test showed a genetic marker in the ACTN3 gene: https://www.malacards.org/search/results?q=ACTN3%20gene%20and%20Spinal%20Muscular%20Atrophy%20(SMA) A 2015 MRI revealed ankylosing spondylitis, multiple Tarlov cysts, stenosis at L4 and L5, spinal canal narrowing, and widespread degenerative changes. Surgery on L4 and L5 ...
Read more